Vysoce dávkovaná terapie a autologní transplantace u pacientů s difuzním velkobuněčným B lymfomem v 1. kompletní nebo parciální remisi

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00007645" target="_blank" >RIV/61989592:15110/08:00007645 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission

Popis výsledku v původním jazyce

Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy /HDT) followed by autologous stem cell transplantation (ASCT) in firts complete remission. Reprospective studies hase suggestedthat HDT with ASCT can improve survival also in partial responders but some doubt about the advantage of intensive therapy in such patients still remain. We evaluated retrospectively the results of hDT and ASCT in 55 patients with confirmed DLBCL treated between may 1999 and July 2006. Thirty-six patients (65%) showed partial remission (PR) and 19 patients (35%) reached complete remission (CR) after induction treatment with (44%) or without (56%) concomitant ritusimab (R) immunotherapy. After HDT a ASCT, 69% of patients fulfilled the criteria of CR, 22 % had unconfirmed CR (CRu), 7%remained in PR and 1 patient (2%) relapsed. Twenty patients in PR after the induction treatment reached CR after ASCT, 12 other PR patients achieved CRu. Th

Název v anglickém jazyce

High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission

Popis výsledku anglicky

Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy /HDT) followed by autologous stem cell transplantation (ASCT) in firts complete remission. Reprospective studies hase suggestedthat HDT with ASCT can improve survival also in partial responders but some doubt about the advantage of intensive therapy in such patients still remain. We evaluated retrospectively the results of hDT and ASCT in 55 patients with confirmed DLBCL treated between may 1999 and July 2006. Thirty-six patients (65%) showed partial remission (PR) and 19 patients (35%) reached complete remission (CR) after induction treatment with (44%) or without (56%) concomitant ritusimab (R) immunotherapy. After HDT a ASCT, 69% of patients fulfilled the criteria of CR, 22 % had unconfirmed CR (CRu), 7%remained in PR and 1 patient (2%) relapsed. Twenty patients in PR after the induction treatment reached CR after ASCT, 12 other PR patients achieved CRu. Th

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neoplasma

ISSN

0028-2685

e-ISSN

—

Svazek periodika

55

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

SK - Slovenská republika

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—